bgne buy strong product sale
pipelin event approach month
abraxan revlimid vidaza sale china reinforc posit view sale
potenti drug china new pipelin disclosur includ guidanc
enrol complet phase trial zanubrutinib compar br patient
previous untreat cll top-lin phase result patient waldenstrom
macroglobulinemia wm guid year new trial initi tislelizumab
lifirafenib raf dimer inhibitor updat estim maintain buy
strong product sale reinforc optimist view potenti bgne
portfolio china bgne report revenu consist product
sale collabor revenu product sale deriv abraxan revlimid
vidaza china grew vs low due season oncolog
product sale china see preview maintain posit view sale
growth potenti three drug china given lack class competitor
product improv market access bgne capabl leverag market
expertis local player second largest oncolog sale forc china sg
expens respect lower consensu
compani end quarter cash equival invest
updat estim reflect result
zanubrutinib updat global zanubrutinib phase trial relapsed/refractori
treatment-na patient waldenstrom macroglobulinemia wm remain track
top-lin data releas year bgne present data singl arm cohort
patient eha annual congress june chronic lymphocyt
leukaemia cll global phase trial compar zanubrutinib bendamustin
plu rituximab br cll guid complet patient enrol bgne
continu guid us nda submiss zanubrutinib earli china
nda zanubrutinib treatment r/r mantl cell lymphoma mcl r/r cll
review compani expect regulatori decis year data
updat upcom confer includ wm cohort global phase studi
eha annual congress ii month updat china phase ii studi cll
mcl iii mcl cohort global phase ii studi iv cll fl cohort
phase combo studi gazyva confer jun
tislelizumab announc initi ph front-lin studi china tislelizumab
combin chemotherapi patient recurr metastat nasopharyng
cancer npc preliminari data tislelizumab chines patient npc earli
stage studi present meet top-lin result asia
pivot ph ii studi urotheli cancer announc follow submiss
nda china potenti nda approv china treatment patient r/r
classic hodgkin lymphoma guid us top-lin result global
ph ii studi patient hepatocellular carcinoma expect
follow regulatori discuss agenc enrol four on-going ph
studi lung liver cancer complet enrol
pamiparib updat top-lin result china pivot phase ii studi patient
previous treatment ovarian cancer announc late earli
collabor program updat bgne expect partner dose first patient
phase ib studi evalu zanu combin inhibitor
phase ib studi on-going evalu combin bgne lifirafenib raf dimmer
inhibitor srpingwork mek inhibitor patient
advanc refractori solid tumor harbor ra mutat raf mutat
page analyst certif import disclosur
valuat risk
valu bgne per share use dcf-base valuat method valuat
includ commerci product bgne acquir celg part collabor
includ abraxan revlimid vidaza well probability-adjust cash flow deriv
drug candid develop zanubrutinib tislelizumab pamiparib
use discount rate consist commerci stage biotech compani
coverag termin growth rate appli termin year post patent expir
compar similar compani coverag
risk valuat bgne includ regulatori commerci setback potenti
emerg new competitor /or lower product sale expect risk intellectu
properti risk manag execut misstep
page analyst certif import disclosur
amort intang
total incom expens
net incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
